DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc today reported its second quarter 2009 financial results. Elan CEO Kelly Martin said, “During the first six months of 2009, we grew revenues, added an additional approach to Alzheimer’s disease and successfully completed our strategic review with the announcement of a transformative transaction with Johnson & Johnson. Our focus will remain squarely on a disciplined and continuous investment in science and advancing our diversified clinical portfolio to patients.”
